Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 9/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 8/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455709 | 0.81 | LMNA (0.64) | LMNANPSR1AVPR1AAVPR2KDM4E | |
| SCHEMBL13672519 | 0.70 | ALDH1A1 (0.43) | LMNAAVPR1AAVPR2KDM4EALDH1A1 | |
| SCHEMBL13672183 | 0.67 | ALDH1A1 (0.41) | LMNAAVPR1AAVPR2POLBALDH1A1 | |
| SCHEMBL13672416 | 0.65 | ALDH1A1 (0.45) | NPSR1AVPR1AAVPR2POLBALDH1A1 | |
| SCHEMBL10061345 | 0.64 | MAOB (0.55) | KDM4ECAPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1368181 | 0.63 | TP53 (0.63) | KDM4ECAPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2895445 | 0.62 | ALDH1A1 (0.70) | LMNAAVPR1AAVPR2ALDH1A1HPGD | |
| SCHEMBL9254199 | 0.61 | HIF1A (0.52) | KDM4ECAPN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL31123658 | 0.61 | ALDH1A1 (0.60) | LMNANPSR1KDM4ECAPN1ALDH1A1 | |
| SCHEMBL3353599 | 0.61 | KDM4E (0.55) | KDM4ECAPN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264414-A1 | Amide Derivatives and Pharmaceutical Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264414-A1 | Amide Derivatives and Pharmaceutical Use Thereof | HSD11B1, HSD11B2, HSD3B1 | LMNA 3531/4885NPSR1 1604/4885AVPR1A 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.